FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134866616> ?p ?o ?g. }

• W3134866616 abstract "Chronic cerebral hypoperfusion (CCH) is the leading cause of cerebral small vessel disease (CSVD). CCH is strongly associated with blood-brain barrier (BBB) dysfunction and white matter lesions (WMLs) in CSVD. However, the effects of CCH on BBB integrity and components and the cellular and molecular mechanisms underlying the effects of BBB dysfunction remain elusive. Whether maintaining BBB integrity can reverse CCH-induced brain damage has also not been explored.In this study, we established a rat model of CSVD via permanent bilateral common carotid artery occlusion (2VO) to mimic the chronic hypoperfusive state of CSVD. The progression of BBB dysfunction and components of the BBB were assessed using immunostaining, Western blotting, transmission electron microscopy (TEM) and RNA sequencing. We also observed the protective role of imatinib, a tyrosine kinase inhibitor, on BBB integrity and neuroprotective function following CCH. The data were analyzed using one-way or two-way ANOVA.We noted transient yet severe breakdown of the BBB in the corpus callosum (CC) following CCH. The BBB was severely impaired as early as 1 day postoperation and most severely impaired 3 days postoperation. BBB breakdown preceded neuroinflammatory responses and the formation of WMLs. Moreover, pericyte loss was associated with BBB impairment, and the accumulation of serum protein was mediated by increased endothelial transcytosis in the CC. RNA sequencing also revealed increased transcytosis genes expression. BBB dysfunction led to brain damage through regulation of TGF-β/Smad2 signaling. Furthermore, imatinib treatment ameliorated serum protein leakage, oligodendrocyte progenitor cell (OPC) activation, endothelial transcytosis, microglial activation, and aberrant TGF-β/Smad2 signaling activation.Our results indicate that reduced pericyte coverage leads to increased BBB permeability via endothelial transcytosis. Imatinib executes a protective role on the BBB integrity via inhibition of endothelial transcytosis. Maintenance of BBB integrity ameliorates brain damage through regulation of TGF-β/Smad2 signaling following CCH; therefore, reversal of BBB dysfunction may be a promising strategy for CSVD treatment." @default.
• W3134866616 created "2021-03-15" @default.
• W3134866616 creator A5020106780 @default.
• W3134866616 creator A5023660241 @default.
• W3134866616 creator A5024856435 @default.
• W3134866616 creator A5039870328 @default.
• W3134866616 creator A5043138062 @default.
• W3134866616 creator A5048859853 @default.
• W3134866616 creator A5051734663 @default.
• W3134866616 creator A5056742611 @default.
• W3134866616 creator A5067317868 @default.
• W3134866616 creator A5071538298 @default.
• W3134866616 creator A5086842851 @default.
• W3134866616 date "2021-05-05" @default.
• W3134866616 modified "2023-10-13" @default.
• W3134866616 title "Reduction in pericyte coverage leads to blood–brain barrier dysfunction via endothelial transcytosis following chronic cerebral hypoperfusion" @default.
• W3134866616 cites W1506045573 @default.
• W3134866616 cites W1968060691 @default.
• W3134866616 cites W1998907224 @default.
• W3134866616 cites W2034275438 @default.
• W3134866616 cites W2045482803 @default.
• W3134866616 cites W2056856515 @default.
• W3134866616 cites W2102278945 @default.
• W3134866616 cites W2104901197 @default.
• W3134866616 cites W2107325549 @default.
• W3134866616 cites W2109290881 @default.
• W3134866616 cites W2119195037 @default.
• W3134866616 cites W2119810088 @default.
• W3134866616 cites W2128751464 @default.
• W3134866616 cites W2140621953 @default.
• W3134866616 cites W2145252529 @default.
• W3134866616 cites W2158427595 @default.
• W3134866616 cites W2159821105 @default.
• W3134866616 cites W2162189519 @default.
• W3134866616 cites W2168558768 @default.
• W3134866616 cites W2179438025 @default.
• W3134866616 cites W2247287442 @default.
• W3134866616 cites W2550765437 @default.
• W3134866616 cites W2565609152 @default.
• W3134866616 cites W2584173197 @default.
• W3134866616 cites W2606840533 @default.
• W3134866616 cites W2608533759 @default.
• W3134866616 cites W2609511098 @default.
• W3134866616 cites W2761157994 @default.
• W3134866616 cites W2770653478 @default.
• W3134866616 cites W2792673284 @default.
• W3134866616 cites W2804435536 @default.
• W3134866616 cites W2806723635 @default.
• W3134866616 cites W2811101553 @default.
• W3134866616 cites W2890224686 @default.
• W3134866616 cites W2911147760 @default.
• W3134866616 cites W2913141969 @default.
• W3134866616 cites W2913742117 @default.
• W3134866616 cites W2922119358 @default.
• W3134866616 cites W2924029065 @default.
• W3134866616 cites W2946066695 @default.
• W3134866616 cites W2979370432 @default.
• W3134866616 cites W2992544017 @default.
• W3134866616 cites W2993902743 @default.
• W3134866616 cites W2999757271 @default.
• W3134866616 cites W3013784088 @default.
• W3134866616 cites W3014940784 @default.
• W3134866616 cites W3037722266 @default.
• W3134866616 cites W3038979473 @default.
• W3134866616 cites W3044090570 @default.
• W3134866616 cites W3082187751 @default.
• W3134866616 cites W3104682194 @default.
• W3134866616 cites W3110393998 @default.
• W3134866616 cites W3120152290 @default.
• W3134866616 cites W996935101 @default.
• W3134866616 doi "https://doi.org/10.1186/s12987-021-00255-2" @default.
• W3134866616 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8101037" @default.
• W3134866616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33952281" @default.
• W3134866616 hasPublicationYear "2021" @default.
• W3134866616 type Work @default.
• W3134866616 sameAs 3134866616 @default.
• W3134866616 citedByCount "32" @default.
• W3134866616 countsByYear W31348666162021 @default.
• W3134866616 countsByYear W31348666162022 @default.
• W3134866616 countsByYear W31348666162023 @default.
• W3134866616 crossrefType "journal-article" @default.
• W3134866616 hasAuthorship W3134866616A5020106780 @default.
• W3134866616 hasAuthorship W3134866616A5023660241 @default.
• W3134866616 hasAuthorship W3134866616A5024856435 @default.
• W3134866616 hasAuthorship W3134866616A5039870328 @default.
• W3134866616 hasAuthorship W3134866616A5043138062 @default.
• W3134866616 hasAuthorship W3134866616A5048859853 @default.
• W3134866616 hasAuthorship W3134866616A5051734663 @default.
• W3134866616 hasAuthorship W3134866616A5056742611 @default.
• W3134866616 hasAuthorship W3134866616A5067317868 @default.
• W3134866616 hasAuthorship W3134866616A5071538298 @default.
• W3134866616 hasAuthorship W3134866616A5086842851 @default.
• W3134866616 hasBestOaLocation W31348666161 @default.
• W3134866616 hasConcept C123012128 @default.
• W3134866616 hasConcept C126322002 @default.
• W3134866616 hasConcept C142724271 @default.
• W3134866616 hasConcept C170493617 @default.
• W3134866616 hasConcept C185350488 @default.
• W3134866616 hasConcept C202751555 @default.
• W3134866616 hasConcept C2778402981 @default.

• next